Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Base de dados
Tipo de documento
Intervalo de ano de publicação
1.
Toxicon ; 52(4): 551-8, 2008 Sep 15.
Artigo em Inglês | MEDLINE | ID: mdl-18675839

RESUMO

We investigated the myotoxicity of Bothrops jararacussu crude venom and other cytolytic agents on mouse isolated extensor digitorum longus (EDL) and soleus (SOL) muscles, which present distinct properties: EDL is a fast-twitch, white muscle with predominantly glycolytic fibers, while SOL is slow-twitch, red muscle with predominantly oxidative fibers. Muscles were exposed to B. jararacussu crude venom (25 microg/ml) and other crotaline venoms (Agkistrodon contortrix laticinctus; Crotalus viridis viridis; Crotalus durissus terrificus) at the same concentration. Basal creatine kinase (CK) release to bathing solution was 0.43+/-0.06 for EDL and 0.29+/-0.06 for SOL (U g(-)(1) h(-)(1), n=36 for each muscle). Sixty minutes after exposure to B. jararacussu venom, EDL presented higher increase in the rate of CK release than SOL, respectively, 13.2+/-1.5 and 2.9+/-0.7 U g(-)(1)h(-)(1), n=10-12. Muscle denervation, despite decreasing CK content, did not affect sensitivities to B. jararacussu venom. Ouabain and potassium channel blockers (TEA; clotrimazole; glibenclamide) increased the rate of CK release by B. jararacussu in EDL and SOL muscles, decreasing and almost abolishing the different sensitivity. When we exposed EDL or SOL muscles to Naja naja, Apis mellifera venoms (25 microg/ml), or Triton X-100 (0.01%), they showed similar rate of CK release. Our present data suggest that a mechanism involving intracellular calcium regulation or potassium channels may participate in the different sensitivity of EDL and SOL to B. jararacussu venom.


Assuntos
Venenos de Crotalídeos/toxicidade , Músculo Esquelético/efeitos dos fármacos , Bloqueadores dos Canais de Potássio/toxicidade , ATPase Trocadora de Sódio-Potássio/antagonistas & inibidores , Animais , Bothrops , Creatina Quinase/metabolismo , Técnicas In Vitro , Camundongos , Denervação Muscular , Músculo Esquelético/inervação , Músculo Esquelético/patologia , Ouabaína/farmacologia , Canais de Potássio/fisiologia , Testes de Toxicidade
2.
Toxicon ; 50(2): 196-205, 2007 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-17466354

RESUMO

Despite preventing death after snakebites, there is little evidence that polyvalent antivenoms (PAVs) protect against myotoxicity and local damages. We evaluated antibothropic Brazilian PAVs from three manufacturers against the myotoxicity and hemorrhagic activity of Bothrops jararacussu and B. jararaca venoms, respectively, by using two protocols: preincubation of PAVs with venom, and i.v. pretreatment with PAVs, prior to the venom inoculation. In this investigation, we used doses of PAVs ranging from 0.4 to 4.0mL/mg of venom equivalent up to 10 times the amount recommended by the producers for the clinical practice in Brazil. In our preincubation protocol in vivo, PAVs antagonized myotoxicity of B. jararacussu venom by 40-95%, while our pretreatment protocol antagonized myotoxic activity by 0-60%. Preincubation of antivenoms with B. jararaca venom antagonized its hemorrhagic activity by 70-95%, while pretreatment antagonized hemorrhagic activity by 10-50%. Although all PAVs demonstrated partial antagonism against both venoms, the magnitude of these effects varied greatly among the manufactures. The results suggest that the current clinical doses of these PAVs may have negligible antimyotoxic effect.


Assuntos
Antivenenos/uso terapêutico , Bothrops/fisiologia , Venenos de Crotalídeos/antagonistas & inibidores , Venenos de Crotalídeos/toxicidade , Hemorragia/induzido quimicamente , Hemorragia/prevenção & controle , Doenças Musculares/prevenção & controle , Animais , Brasil , Venenos de Crotalídeos/enzimologia , Inibidores Enzimáticos/farmacologia , Técnicas In Vitro , Camundongos , Doenças Musculares/induzido quimicamente , Doenças Musculares/patologia , Necrose , Peptídeo Hidrolases/toxicidade , Fosfolipases/antagonistas & inibidores , Fosfolipases/toxicidade , Inibidores de Proteases/farmacologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA